Ifm_05-may 2022 -

The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo.

A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects. IFM_05-May 2022

If you are looking for guidance based on this study's results: The study demonstrated a clear overall survival benefit

Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice. "late" discontinuation (stopping before or after 3 years),

To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods.

Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen.

The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment.